Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and PD-1 Antibody with Radiotherapy in MSS Metastatic Colorectal Cancer
NCT04030260Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in metastatic colorectal cancer (mCRC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04030260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04030260.